Viatris' (VTRS) Q4 results are likely to gain from momentum in its branded and generic businesses.
Get a deeper insight into the potential performance of Viatris (VTRS) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Chris Davis (Trades, Portfolio), through Davis Advisors, has recently adjusted the firm's holdings in the pharmaceutical company Viatris Inc (NASDAQ:VTRS). On December 31, 2023, the firm reduced its stake in Viatris by 1,402,057 shares. This transaction has altered the landscape of Davis Advisors' investment portfolio, reflecting a strategic move by the firm in the pharmaceutical sector.